--- canonical_name: Thunder God Vine alternate_names: Tripterygium wilfordii, Tripterygium wilfordii Hook F, TwHF, Lei Gong Teng, Leigongteng, Thunder Duke Vine canonical_topic: Thunder God Vine for Health & Longevity short_topic_lc: thunder_god_vine creation_date: 2026-0825-0941 creator_ai_fullname: Opus 5 ep_keywords: Celastrol, Triptolide, Traditional Chinese Medicine, Chinese Herbal Medicine --- # Thunder God Vine for Health & Longevity
Evidence Review created on 08/25/2026 using [AI4L](https://github.com/forever-healthy/AI4L) / Opus 5 **Also known as:** Tripterygium wilfordii, Tripterygium wilfordii Hook F, TwHF, Lei Gong Teng, Leigongteng, Thunder Duke Vine ## Motivation Thunder god vine (*Tripterygium wilfordii*) is a climbing shrub from southern China whose peeled root has been used in Chinese medicine for centuries to calm swollen, painful joints. The root carries two unusually forceful molecules, triptolide and celastrol, that damp down inflammatory signalling far more powerfully than most plant extracts. Chinese hospitals have prescribed standardised root preparations for joint and kidney disease since the 1960s, and Western trials followed. The same potency casts a shadow: the plant is toxic enough to have earned a Chinese nickname about dying within a few steps, and its bark, leaves and flowers have caused fatal poisonings. Interest from the longevity field arrived by a separate route, after laboratory work suggested that celastrol restores the body's sensitivity to the hormone that signals fullness. This review examines what the human and laboratory evidence shows about thunder god vine's effects, how large and how reliable those effects are, the harms recorded alongside them, and how the preparations tested in trials differ from what is sold as a supplement. **[Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol) - [Conclusion](#conclusion)** ## Recommended Reading High-level overviews of thunder god vine's pharmacology, clinical record and toxicity, selected for depth rather than accessibility. * [A Chinese herb Tripterygium wilfordii Hook F in the treatment of rheumatoid arthritis: mechanism, efficacy, and safety](https://pubmed.ncbi.nlm.nih.gov/21365177/) - Bao & Dai, 2011 The clearest single narrative account of how root extracts suppress inflammatory mediators, adhesion molecules and matrix-degrading enzymes, set against the controlled trials available at the time. * [Immunoregulatory effects of Tripterygium wilfordii Hook F and its extracts in clinical practice](https://pubmed.ncbi.nlm.nih.gov/30604167/) - Luo et al., 2019 Synthesises what human studies show about the plant's effects on T-cell and B-cell activity, antibody levels and cytokine secretion, which explains why one herb touches so many different diseases. * [A comprehensive review on celastrol, triptolide and triptonide: Insights on their pharmacological activity, toxicity, combination therapy, new dosage form and novel drug delivery routes](https://pubmed.ncbi.nlm.nih.gov/37062220/) - Song et al., 2023 The most complete compound-level treatment available, covering activity, organ-by-organ toxicity, and the formulation strategies being developed to widen an exceptionally narrow safety margin. * [Therapeutic potential of triptolide in autoimmune diseases and strategies to reduce its toxicity](https://pubmed.ncbi.nlm.nih.gov/34743749/) - Cheng et al., 2021 Pairs the autoimmune efficacy case with a systematic account of dose- and time-dependent damage to liver, kidney, reproductive organs, heart, spleen, lung and gut. * [Treatment of obesity with celastrol](https://pubmed.ncbi.nlm.nih.gov/26000480/) - Liu et al., 2015 The primary paper behind the plant's longevity profile: celastrol, its root triterpene, acts as a sensitiser to leptin (the hormone that signals fullness), producing large weight loss in obese mice. Note to the reader: no relevant article, podcast episode or video on thunder god vine, *Tripterygium wilfordii*, triptolide or celastrol could be located from any of the priority expert platforms, most likely because the plant is a prescription-grade immunosuppressant in China rather than a consumer supplement, and therefore sits outside the topics those platforms cover. Five qualifying high-quality sources were nevertheless identified, so the list is not padded. ## Grokipedia * [Tripterygium wilfordii](https://grokipedia.com/page/Tripterygium_wilfordii) A dedicated botanical and pharmacological article covering the species' taxonomy, root chemistry, traditional and modern medical use, and toxicity, useful for orientation before reading the clinical literature. ## Examine * [Thunder God Vine](https://examine.com/supplements/thunder-god-vine/) Examine's dedicated intervention page summarising the efficacy signal in inflammatory and autoimmune disease alongside its central caution: intrinsic toxicity and a low therapeutic threshold. ## ConsumerLab No ConsumerLab article on thunder god vine exists. ConsumerLab has not tested or reviewed products containing this botanical, which is consistent with its near-absence from the mainstream Western supplement market. ## Systematic Reviews The systematic reviews and meta-analyses below were produced almost entirely by Chinese academic groups working with pharmacopoeial tablets sold by domestic manufacturers whose revenue depends on those products, a conflict of interest that should be weighed against every efficacy estimate they report. * [The effectiveness and safety of Tripterygium wilfordii glycosides combined with disease-modifying anti-rheumatic drugs in the treatment of rheumatoid arthritis: A systematic review and meta-analysis of 40 randomized controlled trials](https://pubmed.ncbi.nlm.nih.gov/33368709/) - Zheng et al., 2021 Forty trials, 3,092 patients: adding the root's glycoside tablets to standard antirheumatic drugs improved joint counts, stiffness and inflammatory markers without excess adverse events. * [Adverse Events Associated With Treatment of Tripterygium wilfordii Hook F: A Quantitative Evidence Synthesis](https://pubmed.ncbi.nlm.nih.gov/31780926/) - Ru et al., 2019 Pooled 46 studies and 2,437 treated participants; adverse events affected 30.75% and severe events 4.68%, spanning gut, reproductive, liver, kidney, blood and skin systems. * [Nephrotoxicity of Tripterygium wilfordii Hook. f Preparations: A Systematic Review and Meta-Analysis](https://pubmed.ncbi.nlm.nih.gov/30431315/) - Feng et al., 2019 Thirty-six studies, 2,017 participants: kidney toxicity occurred in 5.81%, unrelated to disease type, co-medication or duration, though the authors suspect overestimation. * [Tripterygium preparations for the treatment of CKD: a systematic review and meta-analysis](https://pubmed.ncbi.nlm.nih.gov/23664549/) - Zhu et al., 2013 Largest kidney synthesis: 75 trials, 4,386 patients with chronic kidney disease; protein leakage fell substantially, but liver-test abnormalities and menstrual changes rose sharply. * [Efficacy of tripterygium glycosides tablet in treating ankylosing spondylitis: a systematic review and meta-analysis of randomized controlled trials](https://pubmed.ncbi.nlm.nih.gov/26255190/) - Li et al., 2015 Eleven trials, 807 participants: pooled results did not support glycoside tablets for ankylosing spondylitis (inflammatory spinal arthritis), contradicting many individual Chinese trials reporting benefit. ## Mechanism of Action Thunder god vine's activity comes from two root compounds with different targets. Triptolide, a diterpene epoxide, binds [covalently to XPB](https://pubmed.ncbi.nlm.nih.gov/21278739/) (a protein subunit of TFIIH, the general transcription factor that unwinds DNA so genes can be read). Blocking it stalls RNA polymerase II and shuts down the new gene expression on which activated immune cells depend. A [competing account](https://pubmed.ncbi.nlm.nih.gov/27197304/) holds that the decisive event is loss of CDK7 (the kinase that switches that machinery on) and RPB1 (the polymerase's largest subunit) rather than XPB, so the primary target remains contested. Celastrol, a quinone-methide triterpene, works differently. It inhibits NF-ΞΊB (a master switch that turns on inflammatory genes), partially blocks the proteasome (the cell's protein-recycling machine), and activates HSF1 (the heat-shock stress-response regulator). In the hypothalamus it eases endoplasmic reticulum stress (strain in the cell's protein-folding compartment), restoring leptin signalling. Downstream, both [suppress interleukin-6, interleukin-1 and tumour necrosis factor-alpha](https://pubmed.ncbi.nlm.nih.gov/36028187/) β€” the same messengers targeted by modern biologic drugs. Pharmacologically, triptolide is [rapidly and almost completely absorbed by mouth](https://pubmed.ncbi.nlm.nih.gov/30112986/), with exposure that is not dose-proportional. It distributes into liver, heart, spleen, lung and kidney, clears quickly without accumulation on repeat dosing, and under 4% is recovered unchanged. It is a sensitive substrate of CYP3A4 (the liver enzyme that clears most drugs) and of P-glycoprotein (a cellular drug-export pump), and it also [inhibits CYP3A4 and CYP1A2](https://pubmed.ncbi.nlm.nih.gov/26874845/) (a second liver enzyme that clears caffeine and several medicines). No validated human half-life exists; rodent elimination is fast, which is why dosing is three times daily. ## Historical Context & Evolution The plant entered Chinese materia medica not as a tonic but as a poison and a field insecticide. Its common name and the folk warning about dying within a few steps both encode the toxicity of its bark, leaves and flowers; only the peeled root xylem was ever used medicinally, applied for fever, boils, abscesses and swollen joints. Systematic hospital use began in the 1960s, when Chinese rheumatology and dermatology departments started prescribing standardised root extracts for rheumatoid arthritis and skin disease. Standardised tripterygium glycoside tablets subsequently became registered pharmaceutical products in China, and their use spread to lupus, kidney disease, ankylosing spondylitis and urticaria (long-standing hives). The turn toward health optimisation came from two accidental observations. First, in [1986 researchers noticed that male arthritis patients on root extract became infertile, and that the effect reversed on stopping](https://pubmed.ncbi.nlm.nih.gov/7750290/). That finding launched an international male-contraceptive research programme which isolated six antifertility diterpene epoxides and mapped their action on developing sperm β€” evidence that the extract reaches and reshapes tissue far from the joint. Second, in 2015 a [computational screen identified celastrol as a leptin sensitiser, producing large weight loss in obese mice](https://pubmed.ncbi.nlm.nih.gov/26000480/). That single result moved the plant from rheumatology into metabolic and longevity discussion. Western opinion has shifted in both directions: a [National Institutes of Health-funded trial](https://pubmed.ncbi.nlm.nih.gov/19687490/) reported efficacy exceeding a standard comparator, while [independent reviewers](https://pubmed.ncbi.nlm.nih.gov/16487688/) have consistently held that trial quality and toxicity reporting remain too weak to settle the question. Neither position has closed the file. ## Expected Benefits ### High 🟩 🟩 🟩 #### Reduced Rheumatoid Arthritis Disease Activity Root extract lowers tender and swollen joint counts, morning stiffness, pain scores and inflammatory markers in active rheumatoid arthritis, apparently by blocking transcription of inflammatory genes in synovial cells and lymphocytes. The evidence base is unusually strong for a botanical: a National Institutes of Health-funded United States trial, a Chinese multicentre trial against methotrexate, and a [meta-analysis of 40 randomised trials](https://pubmed.ncbi.nlm.nih.gov/33368709/). Caveats matter β€” most trials are open-label, Chinese, and use manufacturer-supplied tablets, and dropout in the United States trial was high. **Magnitude:** In the [multicentre Chinese trial](https://pubmed.ncbi.nlm.nih.gov/24733191/), ACR50 (a 50% improvement in the American College of Rheumatology composite of joint counts, pain and function) was reached at 24 weeks by 55.1% on thunder god vine, 46.4% on methotrexate and 76.8% on the combination; in the [United States trial](https://pubmed.ncbi.nlm.nih.gov/19687490/), ACR20 (the 20% improvement threshold) was 65.0% (95% confidence interval, the range within which the true value most likely falls: 51.6–76.9) versus 32.8% (21.3–46.0) for sulfasalazine. #### Reduced Protein Leakage in Chronic Kidney Disease Across immunoglobulin A nephropathy, membranous nephropathy and lupus nephritis (three immune-driven diseases of the kidney's filtering units) and diabetic kidney disease, root preparations reduce protein loss into urine and raise remission rates, attributed to suppression of the immune attack on the kidney's filtering units and to direct stabilisation of podocytes (the cells forming its filtration barrier). The pooled analysis draws on 75 randomised trials, but most were small, Chinese and methodologically modest, and harms rose in parallel with benefit. **Magnitude:** Protein excretion fell by 628 mg/day (95% confidence interval βˆ’736 to βˆ’521) and serum creatinine by 0.12 mg/dL; complete remission rose 56% and relapse fell 58% ([Zhu et al., 2013](https://pubmed.ncbi.nlm.nih.gov/23664549/)). ### Medium 🟩 🟩 #### Slowed Structural Joint Damage on X-Ray Beyond symptom control, two years of root extract restrained erosion and joint-space narrowing on hand and foot radiographs about as well as methotrexate, the reference structural agent. Structural protection is the outcome that separates a genuine disease-modifying agent from an anti-inflammatory, which makes this the most consequential finding for anyone weighing long-term joint preservation. The grade is held at Medium because the comparison was open-label, non-blinded and lacked a placebo arm, so absolute retardation cannot be isolated. **Magnitude:** Over two years, change in total Sharp score (the standard X-ray damage score), erosion score and joint-space narrowing did not differ significantly between the thunder god vine, methotrexate and combination arms (p > 0.05), and tracked disease-activity change in all three; no placebo-controlled figure for absolute retardation exists ([Zhou et al., 2018](https://pubmed.ncbi.nlm.nih.gov/29636089/)). #### Reduced Systemic Lupus Erythematosus Disease Activity Added to conventional immunosuppression, glycoside tablets lowered lupus activity scores and improved overall response, consistent with broad suppression of T-cell and B-cell activation. Trial sequential analysis (a check on whether enough patients have been studied for the pooled result to be trusted) supported the robustness of the estimate, which is rare in this literature. The evidence remains at Medium because the eight contributing trials were small, all Chinese, and rated low to moderate certainty, and because the comparison is add-on rather than head-to-head against established agents. **Magnitude:** Lupus activity score fell by a mean difference (the average gap between groups) of 1.66 points (95% confidence interval βˆ’2.07 to βˆ’1.26) and overall response rate rose with a relative risk (the ratio of event rates between groups) of 1.21 (1.11–1.32) across eight trials and 538 patients ([Chen et al., 2023](https://pubmed.ncbi.nlm.nih.gov/37601046/)). ### Low 🟩 #### Reduced Chronic Hives Severity As an add-on to antihistamines in antihistamine-resistant chronic urticaria, glycoside tablets improved cure and response rates and reduced itch, weal number and weal size, with immunoglobulin E levels falling alongside. The evidence is a meta-analysis of 27 trials, all Chinese and mostly small ([Li et al., 2023](https://pubmed.ncbi.nlm.nih.gov/36694954/)). **Magnitude:** Cure rate relative risk 1.37 (95% confidence interval 1.15–1.63) and total efficacy relative risk 1.40 (1.30–1.50) across 27 trials and 2,788 patients. #### Reduced Psoriasis Severity Combination regimens improved plaque severity and total response, while monotherapy showed no significant benefit. The pattern suggests the plant works as an add-on rather than a stand-alone treatment in skin disease; the basis is a network meta-analysis of 43 trials, all published in Chinese or English ([Lin et al., 2026](https://pubmed.ncbi.nlm.nih.gov/42378804/)). **Magnitude:** Combination therapy lowered the Psoriasis Area and Severity Index (the standard plaque-severity score) by a mean difference of 3.96 points (95% confidence interval βˆ’5.57 to βˆ’2.35); monotherapy showed no significant difference. #### Reduced Ankylosing Spondylitis Symptoms ⚠️ Conflicted Evidence here is directly contradictory: numerous individual Chinese trials report improved stiffness, pain and swelling, yet the pooled analysis of eleven of them concluded that glycoside tablets do not treat the condition effectively, with spinal mobility moving the wrong way ([Li et al., 2015](https://pubmed.ncbi.nlm.nih.gov/26255190/)). Trial quality was only moderate throughout. **Magnitude:** Morning stiffness improved (mean difference 11.79; 95% confidence interval 3.13–20.45) while the Schober spinal-flexion test worsened (βˆ’0.36; βˆ’0.65 to βˆ’0.07) and the global patient score showed no effect. ### Speculative 🟨 #### Leptin Re-Sensitisation and Fat Loss Celastrol restored leptin sensitivity and [produced up to 45% weight loss in obese mice](https://pubmed.ncbi.nlm.nih.gov/26000480/), and [reduced age-associated obesity in older mice](https://pubmed.ncbi.nlm.nih.gov/30821426/). No controlled human weight study exists; the basis is mechanistic and rodent-only. #### Direct Antitumour Activity Triptolide inhibits growth across the full National Cancer Institute cell-line panel, and a water-soluble synthetic derivative has entered oncology trials. Human evidence is confined to small early-phase studies of that derivative, not the botanical. ## Benefit-Modifying Factors * **CYP3A4 and P-glycoprotein variants:** Triptolide is a sensitive CYP3A4 substrate and P-glycoprotein cargo; poor-metaboliser or low-efflux genotypes raise exposure and apparent efficacy at a given dose, while rapid metabolisers may under-respond to standard tablet strengths. * **Baseline inflammatory markers:** Higher pre-treatment C-reactive protein (a general blood marker of inflammation) and erythrocyte sedimentation rate leave more room for measurable improvement; those already near-normal on other therapy see proportionally smaller gains in joint counts and stiffness. * **Baseline protein leakage:** In kidney disease, absolute reduction in urinary protein scales with starting level; those with heavy leakage gain most, while people with only trace protein have little to gain from an agent carrying this harm profile. * **Sex:** Efficacy appears similar in men and women, but reproductive toxicity is dose-limiting in both, so women of reproductive age and men wishing to conceive are frequently held at lower doses, which reduces the benefit actually achievable. * **Age:** [Pooled analysis](https://pubmed.ncbi.nlm.nih.gov/36028187/) found stronger responses in patients under 45 receiving short intermittent courses, while a [separate synthesis in late-onset disease](https://pubmed.ncbi.nlm.nih.gov/27866179/) (onset at 60 or older) found favourable joint and inflammatory-marker effects from only four low-quality trials, so older adults have a thinner evidence base. * **Pre-existing liver or kidney impairment:** Reduced clearance raises exposure, but forces dose reduction or discontinuation before benefit accrues; in practice, impairment lowers the achievable benefit rather than raising it. ## Potential Risks & Side Effects ### High πŸŸ₯ πŸŸ₯ πŸŸ₯ #### Menstrual Disruption and Ovarian Suppression The most frequent harm, and the reason the plant is effectively unusable in many women of reproductive age. Root extract suppresses ovarian follicular function, producing irregular cycles, scanty periods and amenorrhoea (absence of periods), with premature ovarian insufficiency reported after prolonged high-dose exposure. Reproductive damage is the single largest adverse-event category in pooled analyses, is dose- and duration-dependent, and varies markedly by manufacturer. Cycles usually resume after stopping, but recovery is not universal in older or longer-treated women. **Magnitude:** Reproductive-system adverse reactions occurred in 14% of patients (95% confidence interval 12–17%) in a [79-study pooled safety analysis](https://pubmed.ncbi.nlm.nih.gov/32237477/); altered menstruation carried a relative risk of 5.29 (2.09–13.38) in the [kidney-disease meta-analysis](https://pubmed.ncbi.nlm.nih.gov/23664549/), and seven women in the 69-patient thunder god vine arm of the [multicentre arthritis trial](https://pubmed.ncbi.nlm.nih.gov/24733191/) developed irregular menstruation, against three on methotrexate alone. #### Suppression of Sperm Production The diterpene epoxides act on metamorphosing spermatids and on testicular and epididymal sperm, causing exfoliation, delayed sperm release, head–tail separation and cytoskeletal damage. The effect was potent and reversible enough that it was developed deliberately as a male contraceptive candidate β€” the therapeutic dose for arthritis sits close to the antifertility dose, so this is an expected consequence of effective treatment rather than an idiosyncratic reaction. Recovery follows discontinuation, but the interval is not well characterised. **Magnitude:** Sperm output falls toward infertile ranges during continuous therapeutic dosing and recovers after stopping; the [male-antifertility literature](https://pubmed.ncbi.nlm.nih.gov/7750290/) reports the effect qualitatively and gives no pooled figure for percentage sperm-count reduction in men treated for arthritis. #### Liver Injury Triptolide damages liver cells through several convergent routes: it blocks the pregnane X receptor pathway that would normally switch on its own detoxification, degrades Nrf2 (the master switch for the cell's antioxidant defences), and triggers death of liver-resident immune cells and mitochondrial dysfunction. Because it disables the enzyme that clears it, injury accelerates once it begins. Most cases present as symptomless rises in liver enzymes and resolve on withdrawal, but acute liver failure has been reported, and combining with other liver-cleared drugs is disproportionately dangerous. **Magnitude:** Hepatobiliary damage occurred in 4% of patients (95% confidence interval 3–5%) in the [79-study pooled analysis](https://pubmed.ncbi.nlm.nih.gov/32237477/), and abnormal liver function tests carried a relative risk of 4.03 (2.24–7.25) versus control in the [kidney-disease meta-analysis](https://pubmed.ncbi.nlm.nih.gov/23664549/). #### Gastrointestinal Intolerance Nausea, abdominal pain, diarrhoea and appetite loss are the most common reason for stopping, reflecting direct mucosal toxicity from transcriptional arrest in rapidly dividing gut epithelium. Incidence rises with daily dose and treatment length and is markedly higher on monotherapy than when the tablets are combined with methotrexate at reduced dose. Symptoms usually appear in the first weeks, are dose-reversible, and account for much of the high dropout seen in Western trials. **Magnitude:** Gastrointestinal adverse reactions occurred in 7% of patients (95% confidence interval 6–8%) in the [79-study pooled analysis](https://pubmed.ncbi.nlm.nih.gov/32237477/), within an overall adverse-event rate of 30.75% and a severe-event rate of 4.68% in a [separate synthesis of 46 studies](https://pubmed.ncbi.nlm.nih.gov/31780926/). ### Medium πŸŸ₯ πŸŸ₯ #### Kidney Injury Paradoxically, the same preparations used to protect the kidney in glomerular disease (disease of its filtering units) can injure it, with rising creatinine, reduced filtration and occasional acute tubular damage. The mechanism is thought to be direct tubular-cell toxicity from triptolide accumulating in renal tissue. Incidence did not vary with disease type, co-medication or treatment duration in pooled analysis, which argues for an intrinsic rather than context-dependent effect. The reviewers themselves suspect their figure is inflated by weak source studies. **Magnitude:** Kidney toxicity occurred in 5.81% of patients (95% confidence interval 4.43–7.57) across 36 studies and 2,017 participants ([Feng et al., 2019](https://pubmed.ncbi.nlm.nih.gov/30431315/)). #### Bone-Marrow Suppression Transcriptional blockade hits dividing blood-forming precursor cells, producing leukopenia (low white cells), thrombocytopenia (low platelets) and less often anaemia. Counts typically fall in the first two to three months and recover on withdrawal, but agranulocytosis (near-absent neutrophils) has been reported and is the harm most likely to become life-threatening without monitoring. Risk is amplified when the tablets are combined with methotrexate or other marrow-suppressing agents. **Magnitude:** Blood-system adverse reactions occurred in 4% of patients (95% confidence interval 3–5%) in the [79-study pooled analysis](https://pubmed.ncbi.nlm.nih.gov/32237477/), with incidence correlated to daily dose, treatment course and manufacturer. #### Infection from Immune Suppression ⚠️ Conflicted Evidence here is directly conflicted. Mechanistically the plant is a genuine immunosuppressant that reduces T-cell and B-cell activation, and case reports describe herpes zoster (shingles) and pneumonia during treatment; yet pooled randomised data comparing combination therapy against methotrexate alone show no significant excess of infection. The trials were short, small, excluded high-risk patients and were not designed to detect infection, so absence of a signal is weak reassurance rather than evidence of safety. **Magnitude:** Infection carried a relative risk of 1.37 (95% confidence interval 0.84–2.23) across three trials and 493 participants in the [2023 international consensus evidence synthesis](https://pubmed.ncbi.nlm.nih.gov/37967495/), which was produced by a rheumatology panel whose members' clinical practice and research funding depend on the agents being appraised. ### Low πŸŸ₯ #### Skin Reactions, Pigmentation Change and Hair Loss Rash, itch, dryness, facial pigmentation and diffuse hair thinning occur regularly and are usually cosmetic and reversible, though they are a common reason for discontinuation in dermatology settings. Incidence differs sharply between manufacturers, pointing to variable extract composition rather than a fixed property of the plant. **Magnitude:** Skin and appendage adverse reactions occurred in 6% of patients (95% confidence interval 4–7%) in the [79-study pooled analysis](https://pubmed.ncbi.nlm.nih.gov/32237477/). #### Heart Muscle and Rhythm Toxicity Triptolide accumulates in cardiac tissue and causes dose-dependent myocardial injury and arrhythmia in animals, and heart toxicity has been catalogued in herbal case-report registries. Clinical trials have not systematically measured cardiac endpoints, so human incidence is unknown ([Jiang et al., 2023](https://pubmed.ncbi.nlm.nih.gov/36868013/)). **Magnitude:** Not quantified in available studies. No controlled trial has measured cardiac structure, troponin or rhythm outcomes during treatment, leaving only animal dosing studies and isolated case reports. ### Speculative 🟨 #### Fatal Poisoning from Improperly Prepared Material Bark, leaves, flowers and unpeeled root are far more toxic than root xylem, and ingestion has caused multi-organ failure and death. The basis is isolated case reports and poison-centre records rather than controlled data. #### Bone Density Loss Reduced bone mineral content has been observed in animal studies and is biologically plausible given suppressed sex-hormone output. No controlled human bone-density study exists; the basis is mechanistic and preclinical only. ## Risk-Modifying Factors * **CYP3A4 and CYP3A5 variants:** Reduced-function alleles slow triptolide clearance and raise plasma exposure, moving a standard dose toward the toxic range; the enzyme [handles roughly 94% of triptolide metabolism](https://pubmed.ncbi.nlm.nih.gov/29283173/), so genotype effects are unusually large here. * **ABCB1 (P-glycoprotein) variants:** This gene encodes the pump that exports foreign compounds from liver and gut cells; low-function variants increase intracellular triptolide and are associated with greater hepatic accumulation in preclinical models. * **Baseline liver enzymes and kidney function:** Pre-existing transaminase elevation or reduced estimated filtration rate raises the probability of clinically significant organ injury, because both harm pathways start from an already-narrowed reserve. * **Baseline blood counts:** Low starting white-cell or platelet counts leave no buffer against marrow suppression and convert a modest expected decline into clinically dangerous cytopenia (low blood counts). * **Sex:** Women face ovarian suppression and menstrual disruption as the dominant harm; men face sperm suppression. Reproductive toxicity is the leading adverse-event category in both, and dominates the risk profile for anyone under about 45. * **Age:** Reproductive-age adults carry the highest fertility risk; older adults carry higher renal and haematological risk through reduced clearance and marrow reserve, and were under-represented in the trial populations. * **Dose and treatment duration:** [Serious adverse events rose significantly when treatment ran six months rather than three](https://pubmed.ncbi.nlm.nih.gov/33959100/), and gastrointestinal harm correlates directly with daily dose and course length. * **Concurrent hepatically cleared drugs:** Co-administration with CYP3A4 substrates such as atorvastatin [produces synergistic, not merely additive, liver injury](https://pubmed.ncbi.nlm.nih.gov/33600922/) in preclinical models. ## Key Interactions & Contraindications * **CYP3A4 inhibitors (ritonavir, ketoconazole, clarithromycin, grapefruit juice):** Caution to absolute avoidance. [Ritonavir raised triptolide exposure 6.8-fold in rats](https://pubmed.ncbi.nlm.nih.gov/29283173/) and [grapefruit juice raised it 153%](https://pubmed.ncbi.nlm.nih.gov/30112986/); consequence is dose-multiplied liver, kidney and marrow toxicity. Separation in time does not mitigate; dose reduction or avoidance is required. * **CYP3A4 inducers (rifampicin, carbamazepine, phenytoin, St John's wort):** Caution β€” [dexamethasone pretreatment cut triptolide exposure by 85%](https://pubmed.ncbi.nlm.nih.gov/29283173/) in rats, so induction risks silent loss of efficacy. Mitigation is to avoid the combination rather than to escalate dose blindly. * **CYP3A4 and CYP1A2 substrates (simvastatin, midazolam, ciclosporin, theophylline, tizanidine, caffeine):** Caution. Triptolide [inhibits both enzymes](https://pubmed.ncbi.nlm.nih.gov/26874845/), raising substrate levels and their characteristic toxicities. Mitigation is substrate-level monitoring or dose reduction of the substrate; separating doses does not help with enzyme inhibition. * **Statins, particularly atorvastatin:** Absolute contraindication at full statin dose. Triptolide [blocks the receptor pathway that would normally clear both drugs, producing synergistic liver injury](https://pubmed.ncbi.nlm.nih.gov/33600922/). Where a statin is essential, practice is to substitute a non-CYP3A4 statin such as rosuvastatin with monthly liver enzyme checks. * **Methotrexate and leflunomide:** Caution with clear benefit. [Combination outperforms either alone](https://pubmed.ncbi.nlm.nih.gov/24733191/) for joint disease but adds hepatotoxicity and marrow suppression; standard mitigation is reduced doses of both plus blood count and liver enzyme checks every four weeks. * **Biologic immunosuppressants (tumour necrosis factor inhibitors such as etanercept and adalimumab):** Caution. Additive immune suppression raises infection risk, especially reactivation of latent tuberculosis or hepatitis B. Standard mitigation is screening for both before starting, then surveillance for fever or unexplained infection. * **Over-the-counter analgesics β€” paracetamol/acetaminophen and non-steroidal anti-inflammatory drugs:** Caution. Paracetamol adds hepatic oxidative stress; non-steroidal anti-inflammatory drugs add gastric mucosal injury and reduce kidney perfusion. Mitigation is a paracetamol ceiling under 2 g daily and gastric protection alongside any non-steroidal anti-inflammatory drug. * **Hepatotoxic botanicals (green tea extract, kava, comfrey, black cohosh, high-dose turmeric extracts):** Caution. Additive liver injury on a compound that already disables its own detoxification pathway; the practical mitigation is to remove them for the duration of treatment. * **Immune-suppressing and anti-inflammatory supplements (high-dose omega-3, curcumin, resveratrol, cat's claw, boswellia):** Caution. These share the inflammatory-signalling target and additively blunt immune surveillance and platelet function; effects compound rather than substitute, so total load should be counted. * **Ciclosporin, tacrolimus and mycophenolate:** Caution to avoidance. Additive immunosuppression plus competition for CYP3A4 and P-glycoprotein raises both drug levels and infection risk; requires therapeutic drug monitoring if unavoidable. **Populations who should avoid Thunder god vine:** * Pregnancy and breastfeeding β€” causes fetal malformation and pregnancy loss in animal reproductive-toxicity studies * Anyone seeking conception within 12 months, of either sex, given reversible but slow-recovering ovarian and testicular suppression * Active or chronic liver disease β€” Child-Pugh Class B or C cirrhosis (a liver-failure severity grade), or liver enzymes above twice the upper limit of normal * Advanced kidney disease β€” estimated glomerular filtration rate below 45 mL/min/1.73 mΒ² * Baseline cytopenia (low blood counts) β€” white cells below 4.0 Γ— 10⁹/L, neutrophils below 2.0 Γ— 10⁹/L, or platelets below 100 Γ— 10⁹/L * Active serious infection, untreated latent tuberculosis, or hepatitis B surface antigen positivity without antiviral cover * Known premature ovarian insufficiency, low ovarian reserve, or pre-existing oligospermia (low sperm count) * Children and adolescents under 18 years, in whom gonadal development is at risk ## Risk Mitigation Strategies * **Root-xylem-only sourcing:** Prevents fatal poisoning and severe multi-organ toxicity from bark, leaf and flower material, which carry several-fold higher concentrations of the same toxins; it rests on documentary confirmation of the plant part used. * **Low starting dose with slow titration:** Protocols begin near 10 mg of glycoside tablets twice daily (roughly 0.5 mg/kg/day) and rise to 1–1.5 mg/kg/day over two to four weeks, limiting gastrointestinal intolerance and early liver enzyme rises. * **Hard three-month course ceiling:** [Serious adverse events rose significantly at six months versus three](https://pubmed.ncbi.nlm.nih.gov/33959100/); capping continuous exposure at 12 weeks before a break limits cumulative reproductive, hepatic and renal toxicity. * **Fertility preservation before starting:** Sperm banking for men and egg or embryo freezing for women under 40 pre-empts the possibility that ovarian and testicular suppression does not fully reverse after prolonged use. * **Combination rather than monotherapy dosing:** [Pooled analysis](https://pubmed.ncbi.nlm.nih.gov/32237477/) found gastrointestinal, reproductive and skin toxicity all higher on monotherapy than when tablets were paired with methotrexate at reduced doses of each, for equal or better joint outcomes. * **Scheduled liver, kidney and blood monitoring:** Liver enzymes, creatinine and full blood count at baseline, week 2, week 4, then every 4–8 weeks catch transaminase rises, creatinine drift and cytopenia while they are still reversible. * **Removal of competing liver-cleared drugs:** Withdrawing CYP3A4 substrates and inhibitors β€” statins, azole antifungals, macrolides (an antibiotic class such as clarithromycin), grapefruit juice β€” before starting prevents the synergistic hepatotoxicity that produces the most severe reported cases. * **Single-manufacturer continuity:** Reproductive and skin toxicity [rates differed by manufacturer](https://pubmed.ncbi.nlm.nih.gov/32237477/) in pooled analysis; staying with one verified batch source avoids unpredictable changes in extract potency between refills. ## Therapeutic Protocol * **Standard glycoside-tablet regimen:** Chinese hospital practice uses tripterygium glycoside tablets at 1–1.5 mg/kg/day, typically 10–20 mg three times daily with food, for courses of up to three months before reassessment. * **Trial-validated extract regimens:** The [United States trial](https://pubmed.ncbi.nlm.nih.gov/19687490/) used a root-xylem ethyl acetate extract at 60 mg three times daily; the [Chinese multicentre trial](https://pubmed.ncbi.nlm.nih.gov/24733191/) used 20 mg of root extract three times daily. * **Competing approach β€” monotherapy:** Popularised at Peking Union Medical College Hospital by Xuan Zhang and colleagues, who showed root extract alone was [not inferior to methotrexate over two years](https://pubmed.ncbi.nlm.nih.gov/29636089/) for joint activity and structural damage. * **Competing approach β€” combination with methotrexate:** The same Peking Union group [found combination clearly superior](https://pubmed.ncbi.nlm.nih.gov/24733191/) to either alone; the [2023 international consensus panel](https://pubmed.ncbi.nlm.nih.gov/37967495/) endorses both without ranking them, its members' practice and funding resting on the agents appraised. * **Competing approach β€” conventional Western rheumatology:** Methotrexate escalation followed by biologic or targeted synthetic agents, favoured in European and North American guidelines, which have not incorporated the botanical at all. * **Competing approach β€” topical gel:** Developed at Guang'anmen Hospital of the China Academy of Chinese Medical Sciences to bypass systemic toxicity; efficacy on joint tenderness and swelling remains unclear. * **Best time of day:** Divided across the day with food. [Mouse timing-of-dose work](https://pubmed.ncbi.nlm.nih.gov/32478421/) found liver injury highest with early-rest-phase dosing and lowest twelve hours later, and [celastrol given before the dark phase](https://pubmed.ncbi.nlm.nih.gov/30821426/) disrupted sleep and activity rhythms. * **Half-life and dosing frequency:** No validated human half-life exists; [rodent data](https://pubmed.ncbi.nlm.nih.gov/30112986/) show rapid absorption, fast clearance and no accumulation on repeat dosing, which is why every clinical protocol uses three-times-daily rather than once-daily dosing. * **Split versus single dose:** Always split. Single large doses raise peak concentration, the driver of gastrointestinal and hepatic toxicity, without improving the sustained transcriptional suppression that produces benefit. * **Genetic polymorphisms influencing dose:** CYP3A4 and CYP3A5 genotype [governs roughly 94% of triptolide clearance](https://pubmed.ncbi.nlm.nih.gov/29283173/) and ABCB1 governs its export; reduced-function carriers need lower doses, and no pharmacogenetic dosing algorithm has been validated. * **Sex-based dosing differences:** Efficacy is comparable, but reproductive toxicity is dose-limiting in both sexes, so reproductive-age adults are commonly held at the low end of the range or steered to combination therapy at reduced dose. * **Age-related considerations:** [Response was stronger under 45](https://pubmed.ncbi.nlm.nih.gov/36028187/) with short intermittent courses; adults over 60 have [only four low-quality trials](https://pubmed.ncbi.nlm.nih.gov/27866179/), reduced renal clearance and less marrow reserve, so conservative dosing and tighter monitoring apply. * **Baseline biomarkers influencing response:** Higher baseline C-reactive protein, erythrocyte sedimentation rate and urinary protein predict larger absolute improvement; near-normal baseline values predict little measurable gain against a substantial harm profile. * **Pre-existing conditions influencing response:** Hepatic or renal impairment forces dose reduction that undercuts efficacy; concurrent methotrexate improves response but requires reduced doses of both agents. ## Discontinuation & Cycling * **Not a lifelong agent:** Chinese product labelling and the pooled safety data both point to time-limited use; continuous courses beyond three months raise serious adverse events without evidence of proportionate added benefit. * **No pharmacological withdrawal syndrome:** Stopping produces no dependence or rebound at the receptor level; what patients experience is disease flare as inflammatory suppression lifts, typically within two to six weeks. * **Tapering:** No taper is needed for the drug itself. Practice is to overlap with a maintenance agent such as methotrexate or hydroxychloroquine for four to eight weeks to blunt the flare. * **Cycling is standard practice:** Three months on followed by a break is the common pattern, driven by cumulative toxicity rather than by tolerance; no loss of efficacy on re-exposure has been reported. * **Reproductive recovery during breaks:** Menstrual cycles and sperm output generally recover after discontinuation, and the [reversibility of the antifertility effect](https://pubmed.ncbi.nlm.nih.gov/7750290/) was the original basis for contraceptive development; recovery interval is not well characterised. ## Sourcing and Quality * **Plant part is the single most important variable:** Only peeled root xylem is medicinal. Bark, leaves, flowers and unpeeled root carry far higher toxin loads and have caused fatal poisoning; any product not specifying peeled root xylem should be treated as unsafe. * **Standardisation:** Chinese tripterygium glycoside tablets are registered pharmaceutical products with defined glycoside content, typically 10 mg per tablet. Western "20:1 root extract" capsules carry no triptolide or celastrol assay and are not comparable to trial material. * **Third-party testing:** The relevant document is a batch certificate of analysis quantifying triptolide and celastrol, confirming plant part and species identity by DNA barcoding, and screening for heavy metals and pesticide residue, which accumulate in root crops. * **Manufacturer matters measurably:** [Pooled safety analysis](https://pubmed.ncbi.nlm.nih.gov/32237477/) found female reproductive toxicity clustered in tablets from one province's manufacturer and skin toxicity in another's, so extract composition varies enough between producers to change the harm profile. * **Species substitution:** *Tripterygium hypoglaucum* and *Tripterygium regelii* are sold under overlapping Chinese names with different alkaloid profiles; species should be confirmed as *Tripterygium wilfordii* rather than inferred from the common name. * **No reputable Western brands:** No Western supplement brand or compounding pharmacy is known to produce a pharmaceutical-grade, assayed preparation; Chinese hospital pharmacy tablets remain the only material matching what trials tested. ## Practical Considerations * **Time to effect:** Joint symptoms and inflammatory markers begin improving within four to six weeks; trial response endpoints were measured at twelve and twenty-four weeks, and urinary protein reduction in kidney disease is typically assessed at three months. * **Common pitfall β€” wrong plant material:** Buying whole-plant, bark or leaf products rather than peeled root xylem is the most dangerous and most frequent error, and is the route by which serious poisonings occur. * **Common pitfall β€” treating it as a herb:** Skipping baseline and interval blood tests, or running continuous courses past three months, converts a manageable agent into a hazardous one. It is an immunosuppressant, not a botanical tonic. * **Common pitfall β€” unrecognised interactions:** Continuing a statin, azole antifungal or grapefruit habit multiplies exposure several-fold. Assuming a supplement cannot interact with prescriptions is the second most common source of severe reactions. * **Regulatory status:** Not approved by the Food and Drug Administration and sold in the United States only as an unregulated dietary supplement, while registered as a prescription pharmaceutical in China; the [National Center for Complementary and Integrative Health](https://www.nccih.nih.gov/health/thunder-god-vine) warns risks may exceed benefits. * **Cost, accessibility and payer incentive:** Glycoside tablets cost a few dollars monthly against thousands for biologic antirheumatic drugs, so insurers and national health systems have a financial incentive favouring the cheap option β€” a structural bias in guideline formation and research funding. ## Interaction with Foundational Habits * **Sleep:** Potentially disruptive; direction depends on timing. [Celastrol given to mice just before their active phase](https://pubmed.ncbi.nlm.nih.gov/30821426/) disrupted sleep and activity rhythms and caused lean-mass loss, while shifting it twelve hours earlier preserved rhythms. [Mouse liver toxicity](https://pubmed.ncbi.nlm.nih.gov/32478421/) also varied more than two-fold across the circadian cycle, and clinical protocols fix dose times away from bedtime. * **Nutrition:** Direct and important. [Grapefruit juice raises triptolide exposure by 153%](https://pubmed.ncbi.nlm.nih.gov/30112986/) and must be removed entirely. Doses are taken with food to reduce gastric irritation, the leading cause of discontinuation. Alcohol compounds hepatic stress on a compound that already blocks its own detoxification, and hepatotoxic botanicals in the diet should be removed for the duration. * **Exercise:** Indirect. No study has examined blunting of training adaptation, and the transcriptional target does not obviously intersect muscle hypertrophy signalling. The relevant interaction is immunological: heavy training loads transiently suppress immune function, and stacking that on a genuine immunosuppressant plausibly raises infection risk. That combined load has never been measured in a trial. * **Stress management:** Indirect and mostly favourable. The plant has no direct effect on cortisol output, and the United States trial found [no meaningful change in cortisol or adrenocorticotropic hormone levels](https://pubmed.ncbi.nlm.nih.gov/19687490/). Its practical value here is corticosteroid sparing β€” patients able to reduce prednisone avoid the sleep disruption, mood effects and metabolic strain that steroids impose. ## Monitoring Protocol & Defining Success Before starting, a baseline panel establishes the reserve against which every later result is read: liver enzymes, bilirubin, creatinine with estimated filtration rate, urinary albumin-to-creatinine ratio, full blood count with differential, inflammatory markers, hepatitis B surface antigen, and reproductive hormones with a semen analysis for men who may want children. Anyone starting from an abnormal liver, kidney or count result is in the group the harm data warn about. Ongoing testing is front-loaded because toxicity clusters early: repeat liver enzymes and full blood count at week 2 and week 4, then together with creatinine and urinary protein every 4 weeks through the first three-month course, and every 8–12 weeks on any subsequent course. Inflammatory markers and disease-activity scoring are checked at week 12 and week 24 to decide whether continuation is earning its risk. | Biomarker | Optimal Functional Range | Why Measure It? | Context/Notes | |---|---|---|---| | ALT | 10–26 U/L women, 10–33 U/L men | Earliest signal of liver-cell injury | Alanine aminotransferase, a liver-cell enzyme. Conventional labs flag only above ~40 U/L; functional practitioners act on a doubling from the individual's own baseline. Fasting not required | | AST | 10–26 U/L | Confirms liver injury and flags muscle involvement | Aspartate aminotransferase, a second liver-cell enzyme. Conventional labs flag only above ~40 U/L. Best read paired with ALT; an AST-dominant pattern points to alcohol or muscle rather than drug injury | | Total bilirubin | 0.2–0.8 mg/dL | Distinguishes a harmless enzyme rise from failing liver function | A rise alongside doubled ALT is the combination that mandates immediate discontinuation. Draw fasting; levels rise with fasting beyond 12 hours | | Creatinine and eGFR | eGFR above 80 mL/min/1.73 mΒ² | Detects the kidney toxicity seen in about 1 in 17 users | eGFR is the estimated glomerular filtration rate, a calculated measure of kidney filtering capacity. Conventional cut-off is 60; a 20% fall from personal baseline warrants action well before that. Avoid creatine supplements and heavy meat meals for 48 hours before | | Urine albumin-to-creatinine ratio | Below 10 mg/g | Tracks the primary benefit in kidney disease and detects new filtration-barrier injury | Conventional labs call anything below 30 mg/g normal. First-morning void preferred; exercise and fever transiently raise it | | White cell count with neutrophils | 4.5–8.0 Γ— 10⁹/L total, neutrophils above 2.0 Γ— 10⁹/L | Detects marrow suppression before it becomes dangerous | Neutrophils are the white cells that fight bacteria. Conventional labs accept down to 4.0 Γ— 10⁹/L; on an immunosuppressant a downward trend matters more than the absolute value | | Platelet count | 175–350 Γ— 10⁹/L | Second marker of marrow suppression, often moving before white cells | Conventional reference range runs 150–450 Γ— 10⁹/L. Below 100 Γ— 10⁹/L is a stop signal. Paired with white cell count on the same draw | | hs-CRP | Below 1.0 mg/L | Objective measure of whether inflammatory suppression is working | High-sensitivity C-reactive protein, a general blood marker of inflammation. Conventional cardiovascular cut-off is 3.0 mg/L. Invalid within two weeks of any infection or injury | | ESR | Below 15 mm/h women, below 10 mm/h men | Complements hs-CRP and is the marker used in joint-disease activity scores | Erythrocyte sedimentation rate, how fast red cells settle, a slower inflammation marker. Rises with age and anaemia; interpret alongside haemoglobin | | FSH | 3–8 IU/L, days 2–4 of cycle | Rising values signal the ovarian suppression that is the leading adverse effect | Follicle-stimulating hormone, the pituitary signal driving ovarian and testicular function. Must be drawn on cycle days 2–4 to be interpretable; a rise above 10 IU/L suggests declining ovarian reserve | | AMH | No universal target β€” track change from the individual's own pre-treatment value | Tracks cumulative ovarian damage independently of cycle timing | Anti-MΓΌllerian hormone, a measure of remaining egg supply. Can be drawn on any cycle day | | Semen analysis β€” concentration and motility | Above 16 million/mL, above 42% motile | Directly measures the fertility suppression that is an expected effect | These are lower reference limits; during treatment the meaningful comparison is against the man's own baseline. Requires 2–7 days abstinence | | Hepatitis B surface antigen | Negative | Screens for the latent infection most likely to reactivate under immunosuppression | Baseline only, unless exposure occurs. A positive result requires antiviral cover before starting | Qualitative markers worth tracking alongside the laboratory panel: * Morning stiffness duration in minutes, recorded daily β€” the most responsive early sign that inflammatory suppression is working * Joint pain and swelling on a simple 0–10 scale, since composite trial scores track patient-reported pain closely * Menstrual cycle length, regularity and flow, logged from before the first dose β€” the earliest warning of ovarian suppression * Appetite, nausea and bowel pattern, the leading reasons for discontinuation and an early marker of dose intolerance * Energy levels and exercise tolerance, which distinguish disease control from the fatigue of anaemia or marrow suppression * Skin appearance, facial pigmentation and hair density, which change visibly before laboratory markers move * Frequency and duration of minor infections, the practical proxy for over-suppression when infection markers look normal ## Emerging Research * **Water-soluble triptolide derivative in lung cancer:** [NCT05166616](https://clinicaltrials.gov/study/NCT05166616), a phase 1 study at City of Hope combining Minnelide, a prodrug (an inactive form the body converts to active triptolide), with osimertinib in 8 patients with advanced non-small-cell lung cancer, tests whether it overcomes resistance to targeted therapy. * **Same prodrug in metastatic pancreatic cancer:** [NCT05557851](https://clinicaltrials.gov/study/NCT05557851), a phase 1 trial of 36 patients adding Minnelide to nab-paclitaxel and gemcitabine, sponsored by Minneamrita Therapeutics, whose commercial value rests entirely on a positive result. * **First sub-chronic human safety study of isolated celastrol:** [NCT05494112](https://clinicaltrials.gov/study/NCT05494112) enrolled 35 participants to characterise the safety of purified celastrol in humans. Sponsor Legend Labz sells celastrol products, so independent replication will be needed. * **Celastrol and human sperm motility:** [NCT05413226](https://clinicaltrials.gov/study/NCT05413226), a 5-participant dose-ranging study from the same sponsor, addresses the reproductive question that most constrains use of the whole plant. * **Combination protocol in postmenopausal joint disease:** [NCT04136262](https://clinicaltrials.gov/study/NCT04136262), a phase 2/3 trial of 300 postmenopausal women comparing root extract plus methotrexate against methotrexate, targets the population in whom ovarian toxicity is no longer a limiting concern. * **Toxicity-reduction delivery systems:** Targeted nanocarriers, structural modification and detoxifying co-administration are the main routes being pursued to widen the therapeutic window, reviewed by [Cheng et al., 2021](https://pubmed.ncbi.nlm.nih.gov/34743749/). Success here would change the risk calculation more than any efficacy finding. * **Evidence that could weaken the case β€” duration-dependent harm:** [Li et al., 2021](https://pubmed.ncbi.nlm.nih.gov/33959100/) found serious adverse events significantly higher at six months than three across 31 trials and 2,764 patients, and argued courses should run shorter than three months. * **Evidence that could weaken the case β€” negative pooled results:** The [ankylosing spondylitis meta-analysis](https://pubmed.ncbi.nlm.nih.gov/26255190/) found no effective treatment signal despite many positive individual trials, and the [psoriasis network meta-analysis](https://pubmed.ncbi.nlm.nih.gov/42378804/) found monotherapy ineffective β€” a pattern suggesting publication bias in single-centre reports. ## Conclusion Thunder god vine is not a gentle herb. Its root contains two molecules potent enough to shut down the gene-reading machinery of activated immune cells, and the clinical record reflects that force in both directions. For inflammatory joint disease the evidence is genuinely strong by botanical standards: root extract matched or beat standard drug comparators in controlled trials, held its own on structural joint damage over two years, and worked better still alongside conventional treatment. It also lowers protein loss in kidney disease and reduces lupus activity, with weaker and partly contradictory signals in hives, psoriasis and spinal arthritis. The harms are equally clear and largely predictable. Disruption of ovarian function and sperm production is the leading adverse effect, common enough that the plant was once developed deliberately as a male contraceptive. Liver injury, gut intolerance, kidney damage and bone-marrow suppression all follow dose and duration. Most reverse on stopping; some have not. The quality of the underlying evidence is the weakest link. Almost all trials come from Chinese centres working with tablets from manufacturers whose revenue depends on the result, many did not hide which treatment patients received, and the professional panel that issued treatment guidance is composed of specialists whose practice and funding rest on the agents appraised. Insurers and health systems, meanwhile, have a structural interest in the cheap option over patented alternatives. The plant's effects appear real; how large they are, and at what cost, remains uncertain. **[Top](#top) - [Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol)**